Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company focused on gene therapy for ocular diseases, has announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. The company's president and CEO, Laurent Fischer, M.D., will take part in a fireside chat on August 15, 2024, at 2:00 p.m. ET.
Interested parties can access the webcast of the fireside chat through the Events and Presentations section of Adverum's website, located in the Investors area. The replay of the webcast will remain available on the website for a minimum of 30 days following the presentation, allowing those unable to attend the live event to catch up on the discussion.
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), un'azienda in fase clinica focalizzata sulla terapia genica per le malattie oculari, ha annunciato la sua partecipazione alla 4° Conferenza Virtuale Annuale di Oculistica H.C. Wainwright. Il presidente e CEO dell'azienda, Laurent Fischer, M.D., parteciperà a un colloquio informale il 15 agosto 2024, alle 14:00 ET.
Le parti interessate possono accedere alla trasmissione in diretta del colloquio informale attraverso la sezione Eventi e Presentazioni del sito web di Adverum, situata nell'area Investitori. La registrazione della trasmissione rimarrà disponibile sul sito per un minimo di 30 giorni dopo la presentazione, consentendo a coloro che non possono partecipare all'evento dal vivo di recuperare la discussione.
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), una empresa en etapa clínica enfocada en la terapia génica para enfermedades oculares, ha anunciado su participación en la 4ª Conferencia Virtual Anual de Oftalmología H.C. Wainwright. El presidente y CEO de la empresa, Laurent Fischer, M.D., participará en una charla informal el 15 de agosto de 2024, a las 2:00 p.m. ET.
Las partes interesadas pueden acceder a la transmisión en vivo de la charla a través de la sección de Eventos y Presentaciones del sitio web de Adverum, ubicada en el área de Inversores. La repetición de la transmisión estará disponible en el sitio por un mínimo de 30 días después de la presentación, permitiendo a aquellos que no pueden asistir al evento en vivo ponerse al día con la discusión.
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), 안질환에 대한 유전자 치료에 집중하는 임상 단계의 회사가 H.C. Wainwright 제4회 연례 안과 가상 회의에 참가한다고 발표했습니다. 회사의 사장 겸 CEO인 Laurent Fischer, M.D.는 2024년 8월 15일 오후 2시 ET에 진행되는 질의응답 세션에 참석할 예정입니다.
관심 있는 분들은 Adverum 홈페이지 투자자 페이지 내의 이벤트 및 발표 섹션을 통해 질의응답 세션의 웹캐스트에 접근할 수 있습니다. 웹캐스트 재생은 발표 후 최소 30일 동안 웹사이트에서 제공되어, 실시간 이벤트에 참석할 수 없는 분들이 논의를 따라잡을 수 있도록 합니다.
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), une entreprise en phase clinique axée sur la thérapie génique pour les maladies oculaires, a annoncé sa participation à la 4e Conférence Virtuelle Annuelle d'Ophthalmologie H.C. Wainwright. Le président et PDG de l'entreprise, Laurent Fischer, M.D., participera à une discussion informelle le 15 août 2024 à 14h00 ET.
Les parties intéressées peuvent accéder à la diffusion en direct de la discussion informelle via la section Événements et Présentations du site Web d'Adverum, située dans la zone Investisseurs. La rediffusion de la diffusion sera disponible sur le site pendant au moins 30 jours suivant la présentation, permettant à ceux qui ne peuvent pas assister à l'événement en direct de se rattraper sur la discussion.
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), ein Unternehmen in der klinischen Phase, das sich auf Gentherapien für Augenkrankheiten spezialisiert hat, hat seine Teilnahme an der 4. jährlichen virtuellen Augenheilkunde-Konferenz von H.C. Wainwright bekannt gegeben. Der Präsident und CEO des Unternehmens, Laurent Fischer, M.D., wird am 15. August 2024 um 14:00 Uhr ET an einem informellen Gespräch teilnehmen.
Interessierte können den Webcast des informellen Gesprächs über den Bereich Veranstaltungen und Präsentationen auf der Webseite von Adverum, die sich im Investorenbereich befindet, aufrufen. Die Wiederholung des Webcasts wird mindestens 30 Tage nach der Präsentation auf der Webseite verfügbar sein, sodass diejenigen, die nicht an der Live-Veranstaltung teilnehmen können, die Diskussion nachholen können.
- None.
- None.
REDWOOD CITY, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will participate in a fireside chat at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15, 2024 at 2:00 p.m. ET.
The webcast of the fireside chat may be accessed under Events and Presentations in the Investors section of Adverum’s website. A replay of the webcast will be available on the website for at least 30 days following the presentation.
About Adverum Biotechnologies
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit www.adverum.com.
Inquiries:
Adverum Investor Relations
Email: ir@adverum.com
FAQ
When is Adverum Biotechnologies (ADVM) participating in the H.C. Wainwright Ophthalmology Conference?
Who will represent Adverum Biotechnologies (ADVM) at the H.C. Wainwright conference?
How can I access the webcast of Adverum Biotechnologies' (ADVM) presentation at the H.C. Wainwright conference?
How long will the replay of Adverum Biotechnologies' (ADVM) conference presentation be available?
